Jamie L. Renbarger, MD, MS
Professor of Pediatrics
My career path has been driven by my passion for taking care of patients, developing relationships, and teaching. During my initial pediatric rotation as a third year medical student, I found that I loved caring for children because of their resiliency and innocence. I was also attracted to pediatrics because of the multitude of academic opportunities in the field. Early in my residency, I developed a passion for pediatric hematology/oncology as well as pediatric critical care, attracted by the medical and psychosocial intensities of both fields. Within pediatric hematology/oncology, I was particularly drawn to the clinical care of pediatric hematopoietic stem cell transplant patients and ultimately chose this over critical care due to the opportunity to develop long-term relationships with patients and their families who we have the privilege to see for many years. I embarked upon my pediatric hematology/oncology fellowship training at Baylor College of Medicine with an open mind and an interest in getting good research experience as a foundation for my future academic career. I have always enjoyed thinking about medications, their mechanisms of action, and variability in both response and side effects. As such I decided to join the cancer pharmacology group for my fellowship research. I became passionate about developing ways to predict response to specific therapies we use in children with cancer and, in particular, understanding inter-individual variability in responses and toxicities. My hope is that my passion and research will lead to a better understanding on how to best treat individual children with cancer where the ultimate, initial goal is disease cure rather than control of symptoms. I feel privileged to come to work and think about ways to improve our approaches to caring for our patients.
Smith, E. M. L., Li, L., Chiang, C., Thomas, K., Hutchinson, R., Wells, E. M., Ho, R. H., Skiles, J., Chakraborty, A., & Renbarger, J. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphocytic leukemia. J Peripher Nerv Syst. 2015 Mar;20(1):37-46. doi: 10.1111/jns.12114.
Jayachandran D, Ramkrishna U, Skiles J, Renbarger J, Ramkrishna D. Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression. CPT Pharmacometrics Syst Pharmacol. 2014 Apr 16;3:e110.
Topletz AR, Dennison JB, Barbuch RJ, Hadden CE, Hall SD, Renbarger JL. The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine. Drug Metab Dispos. 2013 Sep;41(9):1651-61.
Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J. Measuring Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. Cancer Nurs. 2013 Sep-Oct;36(5):E49-60. [Epub ahead of print]
Nalepa G, Barnholtz-Sloan J, Enzor R, Dey D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, Chen S, Guan X, Chen Y, Renbarger J, Yang FC, Parada LF, Clapp W. The tumor suppressor CDKN3 controls mitosis. J Cell Biol. 2013 Jun 24;201(7):997-1012. doi: 10.1083/jcb.201205125. Epub 2013 Jun 17.
Haas DM, Quinney SK, Clay JM, Renbarger JL, Hebert MF, Clark S, Umans JG, Caritis SN; for the Obstetric-Fetal Pharmacology Research Units Network. Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic. Am J Perinatol. 2012 Aug 8. [Epub ahead of print].
Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012 Jul 15; 59(1):144-8.
Haas DM, Quinney SK, McCormick CL, Jones DR, Renbarger JL. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. J Matern Fetal Neonatal Med. 2011 Jun 7. Epub ahead of print.
Langholz B, Skolnik J, Barrett J, Renbarger J, Seibel N, Zajicek A, Arndt C. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: A retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer. 2011 Aug;57(2):252-7. 2010 Dec 1. Epub ahead of print.
Lehmann AS, Haas DM, McCormick CL, Skaar TC, Renbarger JL. Collection of human genomic DNA from neonates: a comparison between umbilical cord blood and buccal swabs. Am J Obstet Gynecol. 2011 Apr;204(4):362.e1-6. Epub 2011 Feb 16.
Titles & Appointments
- Professor of Medicine
- Professor of Obstetrics & Gynecology
- Caroline Symmes Scholar in Pediatric Cancer Research
- Division Chief, Pediatric Hematology/Oncology
My primary research interest as a pediatric oncologist/stem cell transplant physician is in personalized medicine and pharmacogenomics in the treatment of childhood cancers. Our work involves a major effort to identify biomarkers of drug toxicity and efficacy in the treatment of pediatric cancers. The ultimate goal is to use these biomarkers to develop simple, robust and practical clinical predictors of response to medications in individual patients that can be used to optimize dosing in the treatment of children, many of whom have curable malignancies. I have extensive clinical and translational research experience involving an investigation of biomarkers in a variety of pediatric populations. As a pediatrician trained in both pediatric hematology/oncology and clinical pharmacology, I also serve as Interim Director of the Indiana Institute for Personalized Medicine. I am the co-PI of the Indiana HSCT Biobank (co-PIs S. Paczesny and J. Renbarger), a longitudinal clinic-biologic repository of de-identified samples linked to relevant clinical information. I am also the principal investigator on the Indiana University Center for Pediatric Pharmacology and Precision Medicine (U54HD090215, 9/1/2016 – 8/31/2021), funded by NICHD. As evidence of my establishing IU as a leader in pediatric clinical pharmacology, with a specific focus on optimizing treatments for children with cancer, the Indiana Center for Pediatric Pharmacology was awarded funding from NICHD as one of four centers of excellence in the U.S. for research in pediatric and developmental pharmacology (U54 HD071598, 9/2011-6/2017). I am currently the PI for an NIH T32 postdoctoral training grant (T32 HD069047; Indiana Pediatric Pharmacology Training Program; 5/1/2011 – 4/31/2019) as well as the Recruiting Officer for the IU Pediatric K12 Award (K12 HD068371; PI Clapp, 2/2013-11/2018).
American Association for Cancer Research
American Society for Clinical Pharmacology and Therapeutics
American Society for Pediatric Hematology/Oncology
American Society of Clinical Oncology
Society for Pediatric Research
American Board of Pediatrics - Pediatrics
Desc: Alpha Omega Alpha